427 related articles for article (PubMed ID: 31242184)
1. TIM-1 serves as a receptor for Ebola virus in vivo, enhancing viremia and pathogenesis.
Brunton B; Rogers K; Phillips EK; Brouillette RB; Bouls R; Butler NS; Maury W
PLoS Negl Trop Dis; 2019 Jun; 13(6):e0006983. PubMed ID: 31242184
[TBL] [Abstract][Full Text] [Related]
2. Ebola Virus Requires Phosphatidylserine Scrambling Activity for Efficient Budding and Optimal Infectivity.
Acciani MD; Lay Mendoza MF; Havranek KE; Duncan AM; Iyer H; Linn OL; Brindley MA
J Virol; 2021 Sep; 95(20):e0116521. PubMed ID: 34319156
[TBL] [Abstract][Full Text] [Related]
3. Ebola Virus Binding to Tim-1 on T Lymphocytes Induces a Cytokine Storm.
Younan P; Iampietro M; Nishida A; Ramanathan P; Santos RI; Dutta M; Lubaki NM; Koup RA; Katze MG; Bukreyev A
mBio; 2017 Sep; 8(5):. PubMed ID: 28951472
[TBL] [Abstract][Full Text] [Related]
4. Characterization of Human and Murine T-Cell Immunoglobulin Mucin Domain 4 (TIM-4) IgV Domain Residues Critical for Ebola Virus Entry.
Rhein BA; Brouillette RB; Schaack GA; Chiorini JA; Maury W
J Virol; 2016 Jul; 90(13):6097-6111. PubMed ID: 27122575
[TBL] [Abstract][Full Text] [Related]
5. A Surrogate Animal Model for Screening of Ebola and Marburg Glycoprotein-Targeting Drugs Using Pseudotyped Vesicular Stomatitis Viruses.
Saito T; Maruyama J; Nagata N; Isono M; Okuya K; Takadate Y; Kida Y; Miyamoto H; Mori-Kajihara A; Hattori T; Furuyama W; Ogawa S; Iida S; Takada A
Viruses; 2020 Aug; 12(9):. PubMed ID: 32842671
[TBL] [Abstract][Full Text] [Related]
6. IL-4/IL-13 polarization of macrophages enhances Ebola virus glycoprotein-dependent infection.
Rogers KJ; Brunton B; Mallinger L; Bohan D; Sevcik KM; Chen J; Ruggio N; Maury W
PLoS Negl Trop Dis; 2019 Dec; 13(12):e0007819. PubMed ID: 31825972
[TBL] [Abstract][Full Text] [Related]
7. Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus.
Matassov D; Marzi A; Latham T; Xu R; Ota-Setlik A; Feldmann F; Geisbert JB; Mire CE; Hamm S; Nowak B; Egan MA; Geisbert TW; Eldridge JH; Feldmann H; Clarke DK
J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S443-51. PubMed ID: 26109675
[TBL] [Abstract][Full Text] [Related]
8. Biomechanical characterization of TIM protein-mediated Ebola virus-host cell adhesion.
Dragovich MA; Fortoul N; Jagota A; Zhang W; Schutt K; Xu Y; Sanabria M; Moyer DM; Moller-Tank S; Maury W; Zhang XF
Sci Rep; 2019 Jan; 9(1):267. PubMed ID: 30670766
[TBL] [Abstract][Full Text] [Related]
9. Cell-cell contact promotes Ebola virus GP-mediated infection.
Miao C; Li M; Zheng YM; Cohen FS; Liu SL
Virology; 2016 Jan; 488():202-15. PubMed ID: 26655238
[TBL] [Abstract][Full Text] [Related]
10. Interaction between TIM-1 and NPC1 Is Important for Cellular Entry of Ebola Virus.
Kuroda M; Fujikura D; Nanbo A; Marzi A; Noyori O; Kajihara M; Maruyama J; Matsuno K; Miyamoto H; Yoshida R; Feldmann H; Takada A
J Virol; 2015 Jun; 89(12):6481-93. PubMed ID: 25855742
[TBL] [Abstract][Full Text] [Related]
11. Mucin-Like Domain of Ebola Virus Glycoprotein Enhances Selective Oncolytic Actions against Brain Tumors.
Zhang X; Zhang T; Davis JN; Marzi A; Marchese AM; Robek MD; van den Pol AN
J Virol; 2020 Mar; 94(8):. PubMed ID: 32051271
[TBL] [Abstract][Full Text] [Related]
12. Single-Dose Trivalent VesiculoVax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge.
Matassov D; Mire CE; Latham T; Geisbert JB; Xu R; Ota-Setlik A; Agans KN; Kobs DJ; Wendling MQS; Burnaugh A; Rudge TL; Sabourin CL; Egan MA; Clarke DK; Geisbert TW; Eldridge JH
J Virol; 2018 Feb; 92(3):. PubMed ID: 29142131
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the therapeutic effect of antibodies targeting the Ebola glycoprotein using a novel BSL2-compliant rVSVΔG-EBOV-GP infection model.
Lee HN; McWilliams IL; Lewkowicz AP; Engel K; Ireland DDC; Kelley-Baker L; Thacker S; Piccardo P; Manangeeswaran M; Verthelyi D
Emerg Microbes Infect; 2021 Dec; 10(1):2076-2089. PubMed ID: 34674613
[TBL] [Abstract][Full Text] [Related]
14. Direct Intracellular Visualization of Ebola Virus-Receptor Interaction by
Mittler E; Alkutkar T; Jangra RK; Chandran K
mBio; 2021 Jan; 12(1):. PubMed ID: 33436438
[TBL] [Abstract][Full Text] [Related]
15. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J
J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907
[No Abstract] [Full Text] [Related]
16. Growth-Adaptive Mutations in the Ebola Virus Makona Glycoprotein Alter Different Steps in the Virus Entry Pathway.
Ruedas JB; Arnold CE; Palacios G; Connor JH
J Virol; 2018 Oct; 92(19):. PubMed ID: 30021890
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of propagation-restricted vesicular stomatitis virus encoding Ebola virus glycoprotein in guinea pigs.
Locher S; Schweneker M; Hausmann J; Zimmer G
J Gen Virol; 2018 Jul; 99(7):866-879. PubMed ID: 29869979
[TBL] [Abstract][Full Text] [Related]
18. Role of the phosphatidylserine receptor TIM-1 in enveloped-virus entry.
Moller-Tank S; Kondratowicz AS; Davey RA; Rennert PD; Maury W
J Virol; 2013 Aug; 87(15):8327-41. PubMed ID: 23698310
[TBL] [Abstract][Full Text] [Related]
19. VSVΔG/EBOV GP-induced innate protection enhances natural killer cell activity to increase survival in a lethal mouse adapted Ebola virus infection.
Williams KJ; Qiu X; Fernando L; Jones SM; Alimonti JB
Viral Immunol; 2015 Feb; 28(1):51-61. PubMed ID: 25494457
[TBL] [Abstract][Full Text] [Related]
20. A Naturally Occurring Polymorphism in the Base of Sudan Virus Glycoprotein Decreases Glycoprotein Stability in a Species-Dependent Manner.
Lennemann NJ; Dillard J; Ruggio N; Cooney AL; Schaack GA; Davey RA; Maury W
J Virol; 2021 Aug; 95(18):e0107321. PubMed ID: 34232742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
